As Swiss pharma giant Roche (ROG: SIX) starts facing up to biosimilars competition for some of its mega-selling biological drugs, yet another copy version has emerged.
Singapore-based Prestige BioPharma and privately-held US generics drugmaker Alvogen have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s trastuzumab biosimilar (HD201; Hervelous) in Central and Eastern Europe.
Hervelous is a monoclonal antibody (MAb) biosimilar to Roche’s Herceptin (trastuzumab), which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, and generated sales last year of $7.4 billion. Hervelous is in Phase III clinical development for filing with the European Medicines Agency and the US Food and Drug Administration in 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze